Search

Search results

399 results found

Safety of guselkumab in patients with moderate-to-severe psoriasis treated through 100 weeks: a pooled analysis from the randomized VOYAGE 1 and VOYAGE 2 studies.

Reich, K, K A Papp, A W Armstrong, Y Wasfi, S Li, Y K Shen, B Randazzo, M Song, and A B Kimball. 2019. “Safety of Guselkumab in Patients With Moderate-to-Severe Psoriasis Treated through 100 Weeks: A Pooled Analysis from the Randomized VOYAGE 1 and VOYAGE 2 Studies.”. The British Journal of Dermatology 180 (5): 1039-49.

Long-term safety profile of ixekizumab in patients with moderate-to-severe plaque psoriasis: an integrated analysis from 11 clinical trials.

Langley, R G, A B Kimball, H Nak, W Xu, B Pangallo, O O Osuntokun, N Agada, and K Reich. 2019. “Long-Term Safety Profile of Ixekizumab in Patients With Moderate-to-Severe Plaque Psoriasis: An Integrated Analysis from 11 Clinical Trials.”. Journal of the European Academy of Dermatology and Venereology : JEADV 33 (2): 333-39.